Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Castelli

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Clinical Chemistry and Laboratory Medicine|June 13, 2015
The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunityMaddalena Alessandra Wu, Roberto Castelli
Immunopharmacology and Immunotoxicology|November 10, 2012
Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinicRoberto Castelli, Andrea Zanichelli, Massimo Cugno
Vascular Medicine (London, England)|January 29, 2005
The heparins and cancer: review of clinical trials and biological propertiesRoberto Castelli, Fernando Porro, Paolo Tarsia
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2014
Thrombosis and hemostatic abnormalities in hematological malignanciesRiccardo Colombo, Paolo Gallipoli, Roberto Castelli
Autoimmunity Reviews|November 19, 2008
Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferationMassimo Cugno, Roberto Castelli, Marco Cicardi
Disease Markers|December 11, 2013
Rheumatoid factors: clinical applicationsFrancesca Ingegnoli, Roberto Castelli, Roberta Gualtierotti
Medical Oncology (Northwood, London, England)|February 9, 2018
The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromesRoberto Castelli, Riccardo Schiavon, Giorgio Lambertenghi Deliliers
Medical Oncology (Northwood, London, England)|December 31, 2017
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomasRoberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Mediterranean Journal of Hematology and Infectious Diseases|July 15, 2016
Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly PatientsRoberto Castelli, Antonio Gidaro, Giorgio Lambertenghi Deliliers
Critical Reviews in Oncology/Hematology|March 16, 2013
Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationshipRoberto Castelli, Andrea Zanichelli, Marco Cicardi, et al.
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Clinical Chemistry and Laboratory Medicine|June 13, 2015
The Janus faces of acquired angioedema: C1-inhibitor deficiency, lymphoproliferation and autoimmunityMaddalena Alessandra Wu, Roberto Castelli
Immunopharmacology and Immunotoxicology|November 10, 2012
Therapeutic options for patients with angioedema due to C1-inhibitor deficiencies: from pathophysiology to the clinicRoberto Castelli, Andrea Zanichelli, Massimo Cugno
Vascular Medicine (London, England)|January 29, 2005
The heparins and cancer: review of clinical trials and biological propertiesRoberto Castelli, Fernando Porro, Paolo Tarsia
Clinical Lymphoma, Myeloma & Leukemia|July 15, 2014
Thrombosis and hemostatic abnormalities in hematological malignanciesRiccardo Colombo, Paolo Gallipoli, Roberto Castelli
Autoimmunity Reviews|November 19, 2008
Angioedema due to acquired C1-inhibitor deficiency: a bridging condition between autoimmunity and lymphoproliferationMassimo Cugno, Roberto Castelli, Marco Cicardi
Disease Markers|December 11, 2013
Rheumatoid factors: clinical applicationsFrancesca Ingegnoli, Roberto Castelli, Roberta Gualtierotti
Medical Oncology (Northwood, London, England)|February 9, 2018
The impact of anaemia, transfusion dependency, comorbidities and polypharmacy in elderly patients with low-risk myelodysplastic syndromesRoberto Castelli, Riccardo Schiavon, Giorgio Lambertenghi Deliliers
Medical Oncology (Northwood, London, England)|December 31, 2017
First-line treatment with bendamustine and rituximab, in patients with intermediate-/high-risk splenic marginal zone lymphomasRoberto Castelli, Luigi Bergamaschini, Giorgio Lambertenghi Deliliers
Mediterranean Journal of Hematology and Infectious Diseases|July 15, 2016
Bendamustine and Rituximab, as First Line Treatment, in Intermediate, High Risk Splenic Marginal Zone Lymphomas of Elderly PatientsRoberto Castelli, Antonio Gidaro, Giorgio Lambertenghi Deliliers
Critical Reviews in Oncology/Hematology|March 16, 2013
Acquired C1-inhibitor deficiency and lymphoproliferative disorders: a tight relationshipRoberto Castelli, Andrea Zanichelli, Marco Cicardi, et al.
Pageof 7